Harmony Biosciences Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M |
| Cost of revenue | $198.3M | $156.8M | $121.2M | $83.5M | $55.5M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M |
| Research and development | $189.6M | $145.8M | $76.1M | $70.9M | $30.4M |
| Operating expenses | $461.6M | $367.1M | $268.8M | $234.2M | $162.4M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M |
| Interest expense | $14.6M | $17.5M | $23.8M | $18.8M | $24.2M |
| Pretax income | $215.1M | $191.8M | $173.4M | $104.7M | $37.4M |
| Income tax expense | $56.4M | $46.3M | $44.5M | -$76.8M | $2.8M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M |
| Balance Sheet | |||||
| Cash and equivalents | $752.5M | $453.0M | $311.7M | $243.8M | $234.3M |
| Current assets | $907.0M | $579.3M | $451.1M | $400.3M | $284.4M |
| Total assets | $1.3B | $999.2M | $811.4M | $673.9M | $433.4M |
| Current liabilities | $252.1M | $175.1M | $163.8M | $78.9M | $53.8M |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M |
| Total debt | $165.0M | $181.2M | $196.2M | $197.5M | $199.5M |
| Stockholders' equity | $870.2M | $659.2M | $467.0M | $402.8M | $186.5M |
| Cash Flow Statement | |||||
| Cash from operations | $348.2M | $219.8M | $219.4M | $144.5M | $98.6M |
| Depreciation and amortization | — | $267,000 | $514,000 | $419,000 | $416,000 |
| Stock-based compensation | $44.9M | $42.6M | $31.7M | $26.2M | $15.7M |
| Capital expenditure | $310,000 | $1.2M | $312,000 | $172,000 | $298,000 |
| Free cash flow | $347.9M | $218.7M | $219.1M | $144.3M | $98.3M |
| Share repurchases | — | — | $100.0M | — | — |
Shares outstanding 57.9M · Free float 60.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.